SBFM (Sunshine Biopharma) Accounts Payable : $4.16 Mil (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Accounts Payable?

Sunshine Biopharma's Accounts Payable for the quarter that ended in Sep. 2024 was $4.16 Mil.

Sunshine Biopharma's quarterly Accounts Payable increased from Mar. 2024 ($3.62 Mil) to Jun. 2024 ($4.93 Mil) but then declined from Jun. 2024 ($4.93 Mil) to Sep. 2024 ($4.16 Mil).

Sunshine Biopharma's annual Accounts Payable increased from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($2.80 Mil) but then declined from Dec. 2022 ($2.80 Mil) to Dec. 2023 ($2.59 Mil).

Sunshine Biopharma Accounts Payable Historical Data

The historical data trend for Sunshine Biopharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Accounts Payable Chart

Sunshine Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

0.10

0.06

0.04

2.80

2.59

Sunshine Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Payable	Get a 7-Day Free Trial															2.22	2.59	3.62	4.93	4.16

Sunshine Biopharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Sunshine Biopharma Accounts Payable Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1177 Avenue of the Americas, 5th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.

Executives

Camille Sebaaly	director, officer: CFO and Secretary	14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun	10 percent owner	1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller	director	10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey	director	6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish	director	6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah	director	924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp	10 percent owner	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty	director, 10 percent owner, officer: CEO and President	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki	director, officer: Chief Operating Officer	731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di	director, officer: Chief Operating Officer	3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3